Hardev Pandha

Title: Hardev Pandha: Innovator in Cancer Diagnostics and Treatment

Introduction

Hardev Pandha is a notable inventor based in Surrey, GB, recognized for his contributions to cancer diagnostics and treatment. With a total of three patents, he has made significant strides in the field of oncology, particularly in identifying biomarkers and developing therapeutic methods.

Latest Patents

Among his latest patents, Hardev Pandha has developed methods for diagnosing cancer. These patents describe bladder cancer-specific biomarkers and lung cancer-specific biomarkers that comprise the nucleic acid sequence of the Engrailed-2 (EN2) gene or the amino acid sequence of the encoded EN2 protein. Additionally, he has outlined the uses of these biomarkers in the treatment, diagnosis, monitoring, and imaging of bladder and lung cancers. Another significant patent focuses on abrogating pro-inflammatory cytokine production during oncolytic reovirus therapy. This patent provides methods for treating proliferative disorders by administering reoviruses alongside agents that modulate the expression or activity of pro-inflammatory cytokines.

Career Highlights

Hardev Pandha has worked with esteemed institutions such as the University of Surrey and Oncolytics Biotech Inc. His work has been pivotal in advancing cancer research and therapeutic strategies, showcasing his commitment to improving patient outcomes.

Collaborations

Throughout his career, Hardev has collaborated with notable individuals in the field, including Matthew C. Coffey and Bradley G. Thompson. These collaborations have further enriched his research and innovation efforts.

Conclusion

In summary, Hardev Pandha is a distinguished inventor whose work in cancer diagnostics and treatment has the potential to significantly impact the medical field. His innovative patents and collaborations reflect his dedication to advancing cancer research and improving therapeutic approaches.